FOLFIRINOX is a combination of four chemotherapies used for treating pancreatic cancer. Credit: Ed Uthman / commons.wikimedia.org.

Amplia Therapeutics has reported data demonstrating the efficacy of AMP945 in a preclinical model of pancreatic cancer when used along with FOLFIRINOX treatment.

AMP945 is an orally bioavailable small molecule FAK inhibitor while FOLFIRINOX is a combination of four chemotherapies used for treating pancreatic cancer.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Preclinical studies were conducted at the Garvan Institute of Medical Research in Sydney, Australia. They demonstrated that mice treated with AMP945 as well as FOLFIRINOX showed improved overall survival against FOLFIRINOX alone.

AMP945 was administered in the days preceding FOLFIRINOX treatment (given on a 12-day cycle) which showed an increase in survival compared to FOLFIRINOX-only treated mice.

Amplia CEO and managing director Dr Chris Burns said: “The exciting results from this mouse study further indicate the potential of AMP945 in pancreatic cancer treatment when used in combination with standard-of-care therapies.

“In light of this data, we have filed a patent to cover the use of FAK inhibitors, and particularly AMP945, in combination with FOLFIRINOX and related treatment regimes.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Previously reported preclinical data also demonstrated the benefit of AMP945, gemcitabine and nab-paclitaxel combination.

Additionally, AMP945 showed promising activity in pancreatic cancer models with the two most common first-line chemotherapy regimens to treat the disease.

At present, the compound is undergoing the Phase Ib/IIa ACCENT trial in patients with pancreatic cancer along with gemcitabine and nab-paclitaxel in Australia.